Antitrypanosomal therapy for chronic chagas' disease

New England Journal of Medicine

Volumn 364, Issue 26, 2011, Pages 2527-2534

  Bern, Caryn ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITRYPANOSOMAL AGENT;

ADULT; BLOOD DONOR; CASE REPORT; CHAGAS DISEASE; CHRONIC DISEASE; COMPLETE HEART BLOCK; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE SIZE; HEART LEFT VENTRICLE WALL MOTION; HEART RATE; HEART RIGHT BUNDLE BRANCH BLOCK; HUMAN; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REVIEW; SEROLOGY; SINUS RHYTHM;

EID: 79959793199     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMct1014204     Document Type: Review

References (53)

1. Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet 2010;375:1388-402.
2. Organización Panamericana de la Salud. Estimación cuantitativa de la enfermedad de Chagas en las Americas. Montevideo, Uruguay: Organización Panamericana de la Salud, 2006. (Report no. OPS/HDM/CD/425-06.)
3. Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA 2007;298:2171-81. (Pubitemid 350106656)
4. Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis 2009;49(5):e52-e54.
5. Rassi A Jr, Rassi A, Little WC. Chagas' heart disease. Clin Cardiol 2000;23:883-9.
6. Rassi A Jr, Rassi SG, Rassi A. Sudden death in Chagas' disease. Arq Bras Cardiol 2001;76:75-96.
7. Rassi A Jr, Rassi A, Rassi SG. Predictors of mortality in chronic Chagas disease: a systematic review of observational studies. Circulation 2007;115:1101-8. (Pubitemid 46673172)
8. de Oliveira RB, Troncon LE, Dantas RO, Menghelli UG. Gastrointestinal manifestations of Chagas' disease. Am J Gastroenterol 1998;93:884-9. (Pubitemid 29076970)
9. Köberle F. Chagas' disease and Chagas' syndromes: the pathology of American trypanosomiasis. Adv Parasitol 1968;6:63-116.
10. Marin-Neto JA, Cunha-Neto E, Maciel BC, Simões MV. Pathogenesis of chronic Chagas heart disease. Circulation 2007;115:1109-23. (Pubitemid 46679556)
11. Engman DM, Leon JS. Pathogenesis of Chagas heart disease: role of autoimmunity. Acta Trop 2002;81:123-32. (Pubitemid 34093802)
12. Urbina JA, Docampo R. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol 2003;19:495-501. (Pubitemid 37329658)
13. Tarleton RL. Chagas disease: a role for autoimmunity? Trends Parasitol 2003;19:447-51.
14. Zhang L, Tarleton RL. Parasite persistence correlates with disease severity and localization in chronic Chagas' disease. J Infect Dis 1999;180:480-6. (Pubitemid 30256331)
15. Sosa-Estani S, Segura EL. Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina. Curr Opin Infect Dis 2006;19:583-7. (Pubitemid 44665465)
16. Garcia S, Ramos CO, Senra JF, et al. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrob Agents Chemother 2005;49:1521-8. (Pubitemid 40463384)
17. Rodriques Coura J, de Castro SL. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 2002;97:3-24.
18. Junckerstorff R, Murray RJ, Garcia-Zapata MTA. Benznidazole. In: Grayson ML, Crowe SM, McCarthy JS, et al., eds. Kucers' the use of antibiotics: a clinical review of antibacterial, antifungal and antiviral drugs. 6th ed. London: Hodder Arnold, 2010:2152-4.
19. Murray RJ, Garcia-Zapata MTA. Nifurtimox. In: Grayson ML, Crowe SM, Mc- Carthy JS, et al., eds. Kucers' the use of antibiotics: a clinical review of antibacterial, antifungal and antiviral drugs. 6th ed. London: Hodder Arnold, 2010:2155-63.
20. Pinto Dias JC. The treatment of Chagas disease (South American trypanosomiasis). Ann Intern Med 2006;144:772-4.
21. Docampo R. Sensitivity of parasites to free radical damage by antiparasitic drugs. Chem Biol Interact 1990;73:1-27. (Pubitemid 20041146)
22. Nifurtimox. Washington, DC: US Pharmacopeial Convention, 1995.
23. Cancado JR, Brener Z. Terapeutica. In: Brener Z, Andrade Z, eds. Trypanosoma cruzi e doença de Chagas. Rio de Janeiro: Guanabara Koogan, 1979:362-424.
24. Wegner DH, Rohwedder RW. The effect of nifurtimox in acute Chagas' infection. Arzneimittelforschung 1972;22:1624-35.
25. Marin-Neto JA, Rassi A Jr, Avezum A Jr, et al. The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz 2009;104:Suppl 1:319-24.
26. Villar JC, Marin-Neto JA, Ebrahim S, Yusuf S. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst Rev 2002;(1):CD003463.
27. Tarleton RL, Reithinger R, Urbina JA, Kitron U, Gürtler RE. The challenges of Chagas disease - grim outlook or glimmer of hope? PLOS Med 2007;4(12):e332.
28. Control of Chagas disease: report of a WHO expert committee. WHO Tech Rep Ser 2002;905:1-109.
29. de Andrade AL, Zicker F, de Oliveira RM, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996;348:1407-13. (Pubitemid 26395235)
30. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006;144:724-34. (Pubitemid 46780632)
31. Wegner DH, Rohwedder RW. Experience with nifurtimox in chronic Chagas' infection: preliminary report. Arzneimittelforschung 1972;22:1635-41.
32. Maguire JH, Mott KE, Hoff R, et al. A 3-year follow-up study of infection with Trypanosoma cruzi and electrocardiographic abnormalities in a rural community in northeastern Brazil. Am J Trop Med Hyg 1982;31:42-7. (Pubitemid 12179896)
33. Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg 1998;59:526-9. (Pubitemid 28480704)
34. Junqueira AC, Chiari E, Wincker P. Comparison of the polymerase chain reaction with two classical parasitological methods for the diagnosis of Chagas disease in an endemic region of north-eastern Brazil. Trans R Soc Trop Med Hyg 1996;90:129-32. (Pubitemid 26141079)
35. Basquiera AL, Sembaj A, Aguerri AM, et al. Risk progression to chronic Chagas cardiomyopathy: influence of male sex and of parasitaemia detected by polymerase chain reaction. Heart 2003;89:1186-90. (Pubitemid 37164010)
36. Wincker P, Telleria J, Bosseno MF, et al. PCR-based diagnosis for Chagas' disease in Bolivian children living in an active transmission area: comparison with conventional serological and parasitological diagnosis. Parasitology 1997;114:367-73. (Pubitemid 27144217)
37. Rassi A, Luquetti AO. Specific treatment for Trypanosoma cruzi infection (Chagas disease). In: Tyler KM, Miles MA, eds. American trypanosomiasis. Boston: Kluwer Academic, 2003:117-25.
38. Coura JR, de Abreu LL, Willcox HP, Petana W. Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas' disease, in a field area with interrupted transmission: I. preliminary evaluation. Rev Soc Bras Med Trop 1997;30:139-44. (In Portuguese.)
39. Marin-Neto JA, Rassi A Jr, Morillo CA, et al. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT). Am Heart J 2008;156:37-43. (Pubitemid 351862295)
40. Sosa-Estani S, Cura E, Velazquez E, Yampotis C, Segura EL. Etiological treatment of young women infected with Trypanosoma cruzi, and prevention of congenital transmission. Rev Soc Bras Med Trop 2009;42:484-7.
41. Chagas disease - resources for health professionals - antiparasitic treatment. Atlanta: Centers for Disease Control and Prevention, 2011. (http://www.cdc.gov/parasites/chagas/health-professionals/tx.html.)
42. Castro JA, de Mecca MM, Bartel LC. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Hum Exp Toxicol 2006;25:471-9. (Pubitemid 44384589)
43. Jackson Y, Alirol E, Getaz L, Wolff H, Combescure C, Chappuis F. Tolerance and safety of nifurtimox in patients with chronic chagas disease. Clin Infect Dis 2010;51(10):e69-e75.
44. Pinazo MJ, Muñoz J, Posada E, et al. Tolerance of benznidazole in treatment of Chagas' disease in adults. Antimicrob Agents Chemother 2010;54:4896-9.
45. Pérez-Molina JA, Pérez-Ayala A, Moreno S, Fernández-González MC, Zamora J, López-Velez R. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. J Antimicrob Chemother 2009;64:1139-47.
46. Viotti R, Vigliano C, Lococo B, et al. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther 2009;7:157-63.
47. Urbina JA. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop 2010;115:55-68.
48. Diniz LF, Caldas IS, Guedes PM, et al. Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. Antimicrob Agents Chemother 2010;54:2979-86.
49. Pinazo MJ, Espinosa G, Gállego M, López-Chejade PL, Urbina JA, Gascón J. Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. Am J Trop Med Hyg 2010;82:583-7.
50. Drugs for Neglected Diseases (DNDi). DNDi strategy. 2010. (http://www.treatchagas.org/rd-dndi-strategy.aspx.)
51. Ministério da Saúde. Brazilian consensus on Chagas disease. Rev Soc Bras Med Trop 2005;38:Suppl 3:7-29. (In Portuguese.)
52. Gascón J, Albajar P, Cañas E, et al. Diagnosis, management and treatment of chronic Chagas' heart disease in areas where Trypanosoma cruzi infection is not endemic. Enferm Infecc Microbiol Clin 2008;26:99-106. (In Spanish.)
53. Maguire JH, Hoff R, Sherlock I, et al. Cardiac morbidity and mortality due to Chagas' disease: prospective electrocardiographic study of a Brazilian community. Circulation 1987;75:1140-5. (Pubitemid 17081020)